Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BFLY NYSE:ENOV NASDAQ:LMAT NASDAQ:LQDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFLYButterfly Network$1.41-17.5%$2.09$0.90▼$4.98$422.86M2.453.33 million shs10.64 million shsENOVEnovis$25.74-4.0%$31.04$25.70▼$49.83$1.53B1.71.51 million shs1.34 million shsLMATLeMaitre Vascular$81.04-0.2%$82.52$71.42▼$109.58$1.84B0.82101,135 shs126,468 shsLQDALiquidia Technologies$17.68-5.4%$15.11$8.26▼$20.33$1.60B0.142.40 million shs3.31 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFLYButterfly Network-17.30%-28.24%-28.43%-39.22%+25.89%ENOVEnovis-3.69%-6.51%-22.97%-26.93%-45.97%LMATLeMaitre Vascular-0.25%-1.69%-3.35%+2.97%-6.73%LQDALiquidia Technologies-5.40%-9.80%+46.60%+11.69%+48.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFLYButterfly Network2.6133 of 5 stars3.41.00.00.03.82.50.6ENOVEnovis3.1826 of 5 stars3.43.00.00.02.21.71.9LMATLeMaitre Vascular2.9547 of 5 stars2.23.03.30.02.12.51.3LQDALiquidia Technologies3.3796 of 5 stars4.51.00.00.01.84.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFLYButterfly Network 2.75Moderate Buy$3.50148.23% UpsideENOVEnovis 2.80Moderate Buy$55.60116.01% UpsideLMATLeMaitre Vascular 2.33Hold$97.8320.72% UpsideLQDALiquidia Technologies 3.00Buy$26.8952.09% UpsideCurrent Analyst Ratings BreakdownLatest BFLY, LMAT, LQDA, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025BFLYButterfly NetworkOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/22/2025LMATLeMaitre VascularBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform7/8/2025ENOVEnovisEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$48.00 ➝ $46.007/1/2025BFLYButterfly NetworkCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.006/12/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$23.00 ➝ $25.006/11/2025LQDALiquidia TechnologiesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $23.006/2/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/28/2025LQDALiquidia TechnologiesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$36.00 ➝ $37.005/28/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $23.005/28/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/28/2025LQDALiquidia TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $35.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFLYButterfly Network$82.06M4.25N/AN/A$0.79 per share1.78ENOVEnovis$2.11B0.70$18.52 per share1.39$45.10 per share0.57LMATLeMaitre Vascular$226.26M8.09$2.38 per share34.01$15.00 per share5.40LQDALiquidia Technologies$14M107.96N/AN/A$0.91 per share19.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFLYButterfly Network-$72.49M-$0.29N/AN/AN/A-75.56%-29.97%-21.13%N/AENOVEnovis-$825.49M-$13.95N/A8.07N/A-37.65%5.99%3.44%8/7/2025 (Estimated)LMATLeMaitre Vascular$44.04M$1.9840.9337.352.1419.96%13.53%9.78%8/5/2025 (Estimated)LQDALiquidia Technologies-$130.39M-$1.58N/AN/AN/A-903.80%-177.91%-60.15%8/6/2025 (Estimated)Latest BFLY, LMAT, LQDA, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ENOVEnovis$0.74N/AN/AN/A$555.80 millionN/A8/6/2025Q2 2025LQDALiquidia Technologies-$0.43N/AN/AN/A$3.90 millionN/A8/5/2025Q2 2025LMATLeMaitre Vascular$0.57N/AN/AN/A$62.48 millionN/A5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/8/2025Q1 2025LQDALiquidia Technologies-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million5/2/2025Q1 2025BFLYButterfly Network-$0.09-$0.06+$0.03-$0.06$21.16 million$21.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFLYButterfly NetworkN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.99%N/A40.40%14 YearsLQDALiquidia TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFLYButterfly NetworkN/A6.064.43ENOVEnovis0.522.551.32LMATLeMaitre Vascular0.4816.4913.83LQDALiquidia Technologies2.082.932.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFLYButterfly Network37.85%ENOVEnovis98.45%LMATLeMaitre Vascular84.64%LQDALiquidia Technologies64.54%Insider OwnershipCompanyInsider OwnershipBFLYButterfly Network25.18%ENOVEnovis2.70%LMATLeMaitre Vascular9.50%LQDALiquidia Technologies26.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFLYButterfly Network460247.29 million185.02 millionOptionableENOVEnovis7,36757.12 million55.58 millionOptionableLMATLeMaitre Vascular49022.59 million20.45 millionOptionableLQDALiquidia Technologies5085.49 million62.83 millionOptionableBFLY, LMAT, LQDA, and ENOV HeadlinesRecent News About These CompaniesLiquidia Technologies (NASDAQ:LQDA) Hits New 12-Month High - Here's What HappenedAugust 1 at 6:44 AM | marketbeat.comOppenheimer Keeps Their Sell Rating on Liquidia Technologies (LQDA)August 1 at 5:09 AM | theglobeandmail.comLiquidia Technologies, Inc. (NASDAQ:LQDA) CAO Sells $20,771.02 in StockJuly 31 at 8:04 PM | marketbeat.comLiquidia Technologies (LQDA) Projected to Post Quarterly Earnings on WednesdayJuly 31 at 7:58 AM | marketbeat.comLiquidia Technologies, Inc. (NASDAQ:LQDA) CAO Dana Boyle Sells 1,063 SharesJuly 31 at 7:01 AM | insidertrades.comLiquidia Technologies, Inc. (NASDAQ:LQDA) Given Consensus Rating of "Buy" by AnalystsJuly 30 at 2:47 AM | americanbankingnews.comLiquidia Technologies, Inc. (NASDAQ:LQDA) Given Average Recommendation of "Buy" by AnalystsJuly 30 at 2:45 AM | marketbeat.comLiquidia Technologies (NASDAQ:LQDA) Hits New 52-Week High - Should You Buy?July 26, 2025 | marketbeat.comInsider Selling: Liquidia Technologies, Inc. (NASDAQ:LQDA) Insider Sells 2,526 Shares of StockJuly 24, 2025 | marketbeat.comLiquidia Technologies call volume above normal and directionally bullishJuly 24, 2025 | msn.comLiquidia Technologies, Inc. (NASDAQ:LQDA) Insider Rajeev Saggar Sells 2,526 SharesJuly 24, 2025 | insidertrades.comLiquidia Technologies (NASDAQ:LQDA) Stock Price Up 10.1% - Still a Buy?July 23, 2025 | marketbeat.comLiquidia Meets 80-Plus Relative Strength Rating BenchmarkJuly 23, 2025 | msn.comLiquidia Shows Rising Relative Price Performance; Still Shy Of Key ThresholdJuly 16, 2025 | msn.comInsider Selling: Liquidia Technologies, Inc. (NASDAQ:LQDA) CAO Sells 1,193 Shares of StockJuly 16, 2025 | insidertrades.comLiquidia Technologies, Inc. (NASDAQ:LQDA) CAO Dana Boyle Sells 1,193 SharesJuly 15, 2025 | marketbeat.comLiquidia Technologies, Inc. (NASDAQ:LQDA) Insider Sells $36,785.28 in StockJuly 15, 2025 | marketbeat.comSarah Krepp Sells 2,673 Shares of Liquidia Technologies, Inc. (NASDAQ:LQDA) StockJuly 15, 2025 | marketbeat.comLiquidia Technologies, Inc. (NASDAQ:LQDA) Insider Sells $68,501.16 in StockJuly 15, 2025 | marketbeat.comLiquidia Technologies, Inc. (NASDAQ:LQDA) Insider Sells $76,069.56 in StockJuly 15, 2025 | marketbeat.comLiquidia Technologies, Inc. (NASDAQ:LQDA) General Counsel Russell Schundler Sells 7,836 SharesJuly 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBFLY, LMAT, LQDA, and ENOV Company DescriptionsButterfly Network NYSE:BFLY$1.41 -0.30 (-17.54%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$1.46 +0.05 (+3.19%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.Enovis NYSE:ENOV$25.74 -1.06 (-3.96%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$25.74 0.00 (0.00%) As of 08/1/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.LeMaitre Vascular NASDAQ:LMAT$81.04 -0.20 (-0.25%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$81.10 +0.06 (+0.07%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.Liquidia Technologies NASDAQ:LQDA$17.68 -1.01 (-5.40%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$17.85 +0.17 (+0.96%) As of 08/1/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
